Mineralocorticoid Receptor Antagonists: all 308 studies that test it

Page 2 of 4. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• Effect of Aldosterone on Energy Starvation in Heart FailureCompletedNCT00574119Phase 4Results posted
• Endometrial Safety StudyCompletedNCT00522873Phase 3Results posted
• Diurnal Variation of Plasminogen Activator Inhibitor-1CompletedNCT00515021Phase 4Results posted
• Safety Study of Ethinylestradiol/Drospirenone in DysmenorrheaCompletedNCT00461305Phase 2/3Results posted
• Low-dose Hormone Therapy for Relief of Vasomotor SymptomsCompletedNCT00446199Phase 3Results posted
• Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneCompletedNCT00391846Phase 4Results posted
• A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure MedicinesCompletedNCT00232180Phase 3Results posted
• Spironolactone in Patients With Single Ventricle HeartCompletedNCT00211081Not applicableResults posted
• EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial IschemiaCompletedNCT00187889Phase 4Results posted
• Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)CompletedNCT00141778Phase 2/3Results posted
• PIE II: Pharmacological Intervention in the Elderly IICompletedNCT00123955Phase 3Results posted
• Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionCompletedNCT00094302Phase 3Results posted
• Low-Dose Spironolactone in Hemodialysis Patients With Resistant HypertensionCompletedNCT07888504Phase 4
• MR and Inflammation After PreeclampsiaActive, not recruitingNCT07345845Early Phase 1
• Unmitigated Aldosterone Signaling During Standard Clinical MRA DosingActive, not recruitingNCT07281014Phase 4
• Bioavailability and Bioequivalence Study of Extended Release Torsemide and SpironolactoneCompletedNCT07046975Phase 3
• Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy SubjectsCompletedNCT07015671Phase 3
• Bioequivalence Study of Spironolactone Tablets in Healthy SubjectsCompletedNCT06579053Phase 1
• Pharmacogenetics of Torasemide and Spironolactone in Hypertension TreatmentCompletedNCT06413082Phase 3
• The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial PreparationCompletedNCT06324851Phase 4
• Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibCompletedNCT06250205Phase 1
• A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseCompletedNCT06039826Phase 1
• Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1CompletedNCT06004830Phase 2
• A Study of Milvexian in Healthy Adult FemalesCompletedNCT05706753Phase 1
• Dapagliflozin With or Without Spironolactone for HFpEFCompletedNCT05676684Phase 2/3
• Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in FemalesCompletedNCT05461573Phase 3
• LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult WomenActive, not recruitingNCT05303636Phase 4
• Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19Status unknownNCT04977960Phase 2
• Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.Status unknownNCT04912011Phase 4
• Fibrosis and the FontanCompletedNCT04901975Phase 1/2
• Non-Responsive Diabetic Macular Edema and SpironolactoneWithdrawnNCT04853355Phase 4
• MR Antagonist and LSD1CompletedNCT04840342Phase 4
• Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19Status unknownNCT04826822Phase 3
• Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)WithdrawnNCT04746495Phase 4
• Spironolactone in the Treatment of Heart FailureTerminatedNCT04727073Phase 3
• Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical TrialActive, not recruitingNCT04714710Phase 2
• Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart FailureStatus unknownNCT04618601Phase 4
• Comparative Effectiveness Study of Spironolactone Versus Doxycycline for AcneActive, not recruitingNCT04582383Phase 4
• Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early DementiaCompletedNCT04522739Phase 4
• Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled StudyStatus unknownNCT04465123Phase 3
• The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart FailureStatus unknownNCT04455178Phase 4
• BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalizationStatus unknownNCT04424134Phase 3
• Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) StudyStatus unknownNCT04327232Phase 2
• Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)TerminatedNCT04300881Phase 2
• Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea PatientsWithdrawnNCT04205136Phase 4
• Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR TrialWithdrawnNCT04190433Phase 2
• Spironolactone for Hidradenitis SuppurativaWithdrawnNCT04100083Phase 4
• Non Invasive Assessment of Heart FailureStatus unknownNCT04078425Early Phase 1
• Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis PatientsStatus unknownNCT03953950Phase 4
• Spironolactone for the Treatment of MelasmaWithdrawnNCT03953209Phase 1
• Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial FibrillationActive, not recruitingNCT03929718Early Phase 1
• Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular DegenerationCompletedNCT03744767Phase 2
• Spironolactone Versus Indapamide in Obese and Hypertensive PatientsStatus unknownNCT03626506Not applicable
• Spironolactone and Perioperative Atrial Fibrillation Occurrence in Cardiac Surgery Patients.Status unknownNCT03551548Phase 3
• Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation.Status unknownNCT03536806Phase 4
• Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) StudyCompletedNCT03512860Phase 1
• Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive PatientsCompletedNCT03476616Phase 4
• Hypoglycemia and Autonomic Nervous System Function-BCompletedNCT03429946Phase 4
• Eplerenone as a Supplement to Epidural Steroid InjectionsWithdrawnNCT03418649Phase 4
• Spironolactone Therapy in Chronic Stable Right HF TrialCompletedNCT03344159Phase 4
• Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.CompletedNCT03334682Phase 3
• The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary AngiographyCompletedNCT03329443Phase 2
• Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis PatientsCompletedNCT03314493Phase 3
• Exploring Mechanisms and Morphology of QT Interval ProlongationCompletedNCT03291145Not applicable
• Spironolactone on Acute Kidney Injury in Critically Ill PatientsStatus unknownNCT03206658Phase 3
• Reduction of Left Ventricular Hypertrophy After Eplerenone TherapyCompletedNCT03186742Phase 4
• The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 DiabetesCompletedNCT03174288Not applicable
• This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are ToleratedCompletedNCT03165240Phase 1
• Treatment Choice in Primary DysmenorrheaCompletedNCT03124524Phase 4
• E4/DRSP Ovarian Function Inhibition StudyCompletedNCT03091595Phase 2
• Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous ChorioretinopathyStatus unknownNCT03079141Phase 4
• Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryCompletedNCT03048825Phase 3
• Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal DiseaseCompletedNCT03020303Phase 3
• The Role of Aldosterone in Circulatory Disorders Within Type 2 DiabetesCompletedNCT03017703Not applicable
• "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"CompletedNCT02957630Phase 1/2
• Pharmacokinetics Study of Eplerenone Coated TabletsWithdrawnNCT02957435Phase 1
• Evaluating the Effect of Spironolactone on Hypertrophic CardiomyopathyStatus unknownNCT02948998Phase 4
• The Role of Minerelocorticoid Receptor on Modulating Aldosterone ProductionCompletedNCT02871648Phase 1
• Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female VolunteersCompletedNCT02852681Phase 1
• Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial HypertensionCompletedNCT02832973Phase 4
• Mineralocorticoid Receptor Antagonists in Type 2 DiabetesCompletedNCT02809963Phase 4
• Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial FibrillationStatus unknownNCT02764619Phase 3
• Spironolactone in Atrial FibrillationStatus unknownNCT02673463Phase 4
• Pharmacokinetics of Eplerenone TabletWithdrawnNCT02607657Phase 1
• Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer PatientsStatus unknownNCT02531412Phase 2/3
• Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKDStatus unknownNCT02502981Phase 4
• Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)TerminatedNCT02501213Phase 2
• Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)Active, not recruitingNCT02490904Phase 3
• The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic AlopeciaWithdrawnNCT02483195Phase 4
• Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian PopulationCompletedNCT02462499Phase 4
• High-Dose Aldactone for Treatment of Diuretic Resistant Heart FailureWithdrawnNCT02429388Phase 4
• Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant HypertensionCompletedNCT02426099Phase 4
• Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac SurgeryStatus unknownNCT02417896Not applicable
• Optimum Treatment for Drug-Resistant HypertensionStatus unknownNCT02369081Phase 4
• Eplerenone in the Management of Abdominal Aortic AneurysmsStatus unknownNCT02345590Phase 4
• Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety StudyWithdrawnNCT02299726Phase 2
• A Study of the Beneficial Effects of Eplerenone on Central Serous ChorioretinopathyStatus unknownNCT02215330Phase 2/3
• Residual Renal Function Preservation in Peritoneal Dialysis PatientsStatus unknownNCT02190318Not applicable
• Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot StudyCompletedNCT02167464Not applicable
• Eplerenone For the Treatment of Chronic Central Serous ChorioretinopathyStatus unknownNCT02153125Phase 2

← Mineralocorticoid Receptor Antagonists overview